Insulin pumps outperform daily injections for glycaemic control

Portable insulin pumps are a safe and valuable treatment option for patients with type 2 diabetes whose glycaemic control using conventional insulin injections is inadequate, say the authors of the newly published OpT2mise trial^[1]
.

After six months, glycated haemoglobin (HbA1c) declined by 1.1%, on average, in a study of 168 people randomly assigned to use an insulin pump and by 0.4% in 163 subjects who continued with multiple daily insulin injections.

Those using the pump were also more likely to achieve their HbA1c target, less likely to be either hypo- or hyperglycaemic, and used a lower daily insulin dose.

The study is published in
The Lancet
.